Humulin Regular Kwikpen (Insulin Human (Rdna))

Humulin Regular Kwikpen is indicated for the control of blood glucose in adults and children with diabetes. It is used as part of a comprehensive diabetes management plan that includes diet, exercise, and self‑monitoring.

• Initiation of insulin therapy in type 1 diabetes mellitus.
• Supplemental insulin for type 2 diabetes mellitus when oral agents are insufficient.
• Management of hyperglycemia during illness or stress.
• Adjunctive treatment in diabetic ketoacidosis after initial fluid and electrolyte therapy.
• Adjustment of basal‑bolus regimens for patients requiring rapid‑acting insulin.

• Humulin Regular Kwikpen provides recombinant human insulin that binds to insulin receptors on muscle, adipose, and hepatic cells. Receptor activation triggers the tyrosine kinase pathway, leading to increased translocation of GLUT‑4 transporters and enhanced glucose uptake. In the liver, insulin suppresses gluconeogenesis and promotes glycogen synthesis, thereby lowering circulating glucose concentrations. The overall effect is a rapid reduction in post‑prandial blood glucose levels, with an onset of action within 30 minutes and a peak around 2–3 hours.

Like all insulin products, Humulin Regular Kwikpen may cause adverse reactions. Reported events are grouped by frequency and clinical significance.

Common

• Mild hypoglycemia with shakiness, sweating, or dizziness after a dose.
• Redness, swelling, or itching at the injection site that resolves quickly.
• Localized fat changes (lipodystrophy) appearing as small lumps or depressions.
• Small, temporary weight gain due to fluid retention.
• Nausea or mild abdominal discomfort occurring within an hour of injection.
• Occasional headache not requiring medical treatment.

Serious

• Severe hypoglycemia causing loss of consciousness, seizures, or need for assistance.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Persistent hyperglycemia indicating possible insulin resistance or dosing error.
• Significant edema or worsening heart failure in susceptible patients.

When using Humulin Regular Kwikpen, several precautions should be observed to minimize risks and ensure effective therapy.

• Verify the correct dose and expiration date before each injection.
• Rotate injection sites within the same anatomical region to reduce lipodystrophy.
• Adjust dose during periods of illness, stress, or changes in physical activity.
• Monitor blood glucose frequently, especially when initiating therapy or changing dose.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Pregnant or breastfeeding women should consult a healthcare professional before use.
• Store the pen at controlled room temperature; do not freeze.

Humulin Regular Kwikpen can interact with other medications that affect glucose levels or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment.
• High‑dose beta‑blockers that may mask hypoglycemia symptoms.
• MAO‑inhibitors combined with sympathomimetic agents, increasing risk of hypertensive crisis.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that can potentiate hypoglycemia.
• Thiazide diuretics or corticosteroids that raise blood glucose.
• Alcohol consumption, which can cause delayed hypoglycemia.
• ACE inhibitors or ARBs, which may enhance insulin sensitivity.